Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351390 · ClinicalTrials.gov registry record · NA
Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 152
- Enrollment target
NCT00351390: Completed NA study, sponsored by Massachusetts General Hospital.
NCT00351390 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 152 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00351390, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 152 participants
- Enrollment target
Study Summary
Levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP) a hormone released from the heart in patients with heart failure (HF) are strongly prognostic of adverse events, such as hospitalization or death from HF. Therapies that are beneficial for HF (such as beta blockers or angiotensin converting enzyme inhibitors) tend to lower levels of NT-proBNP in parallel with improvements in outcomes of patients so treated. Importantly, Nt-proBNP levels may identify a patient at high risk for adverse outcome from their HF, even in periods of apparent stability. It remains unclear, however, whether treating patients based on their NT-proBNP concentrations would be associated with better outcomes compared to standard HF therapy without measurement of NT-proBNP values. The goal of the PROTECT study is to evaluate whether treatment of patients with advanced and recently destabilized HF would benefit from NT-proBNP guided HF treatment, compared to standard HF therapy without such 'hormone guided' treatment.
Interventions
- OTHER Drug therapy for HF
- OTHER NT-proBNP guided HF therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351390
The ClinicalTrials.gov registry entry for NCT00351390 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Drug therapy for HF is the first listed.
NCT00351390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00351390 about?
NCT00351390 is a clinical study titled "Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.". Levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP) a hormone released from the heart in patients with heart failure (HF) are strongly prognostic of adverse events, such as hospitalization or death from HF. Therapies that are beneficial for HF (such as beta blockers or angiotensin con...
What is the current status of trial NCT00351390?
This trial is currently completed. It is a NA study. The enrollment target is 152 participants. The study started on 2005-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00351390?
The interventions under investigation include: Drug therapy for HF (OTHER), NT-proBNP guided HF therapy (OTHER).
Who is sponsoring clinical trial NCT00351390?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.